nach oben

Erschienen in:

11.07.2015

Paraventricular Nucleus Infusion of Epigallocatechin-3-O-Gallate Improves Renovascular Hypertension

verfasst von: Qiu-Yue Yi, Jie Qi, Xiao-Jing Yu, Hong-Bao Li, Yan Zhang, Qing Su, Tao Shi, Dong-Mei Zhang, Jing Guo, Zhi-Peng Feng, Mo-Lin Wang, Guo-Qing Zhu, Jin-Jun Liu, Xiao-Lian Shi, Yu-Ming Kang

Erschienen in: Cardiovascular Toxicology | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Oxidative stress plays an important role in the pathogenesis of hypertension. Epigallocatechin-3-O-gallate (EGCG) is the main polyphenol present in green tea and is known for its potent antioxidant and anti-inflammatory properties. In the present study, we hypothesize that EGCG attenuates oxidative stress in the paraventricular nucleus of hypothalamus (PVN), thereby decreasing the blood pressure and sympathetic activity in renovascular hypertensive rats. After renovascular hypertension was induced in male Sprague-Dawley rats by the two-kidney one-clip (2K-1C) method, the rats received bilateral PVN infusion of EGCG (20 μg/h) or vehicle via osmotic minipump for 4 weeks. Our results were shown as follows: (1) Hypertension induced by 2K-1C was associated with the production of reactive oxygen species in the PVN; (2) chronic infusion of EGCG in the PVN decreased stress-related NAD(P)H oxidase subunit gp91^phox and NOX-4 and increased the activity of antioxidant enzymes (SOD-1), also balanced the content of cytokines (IL-1β, IL-6, IL-10 and MCP-1) in the PVN, and attenuated the level of norepinephrine in plasma of 2K-1C rats. Our findings provide strong evidence that PVN infusion of EGCG inhibited renovascular hypertension progression through its potent anti-oxidative and anti-inflammatory activity in the PVN.

Alderman, M. H., & Ogihara, T. (2007). Global challenge for overcoming high blood pressure: Fukuoka Statement, 19 October 2006. Journal of Hypertension, 25, 727.CrossRefPubMed

Lopez, A. D., Mathers, C. D., Ezzati, M., Jamison, D. T., & Murray, C. J. (2006). Global and regional burden of disease and risk factors, 2001: Systematic analysis of population health data. Lancet, 367, 1747–1757.CrossRefPubMed

Kearney, P. M., Whelton, M., Reynolds, K., Muntner, P., Whelton, P. K., & He, J. (2005). Global burden of hypertension: Analysis of worldwide data. Lancet, 365, 217–223.CrossRefPubMed

Behradmanesh, S., & Nasri, H. (2013). Association of serum calcium with level of blood pressure in type 2 diabetic patients. Journal of Nephropathology, 2, 254–257.PubMedPubMedCentral

Lenfant, C., Chobanian, A. V., Jones, D. W., & Roccella, E. J. (2003). Seventh report of the Joint National Committee on the prevention, detection, evaluation, and treatment of high blood pressure (JNC 7): Resetting the hypertension sails. Hypertension, 41, 1178–1179.CrossRefPubMed

Mittal, B. V., & Singh, A. K. (2010). Hypertension in the developing world: Challenges and opportunities. American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation, 55, 590–598.CrossRef

Savoia, C., Burger, D., Nishigaki, N., Montezano, A., & Touyz, R. M. (2011). Angiotensin II and the vascular phenotype in hypertension. Expert Reviews in Molecular Medicine, 13, e11.CrossRefPubMed

Belmonte, S. L., & Blaxall, B. C. (2011). G protein coupled receptor kinases as therapeutic targets in cardiovascular disease. Circulation Research, 109, 309–319.CrossRefPubMedPubMedCentral

Zubcevic, J., Waki, H., Raizada, M. K., & Paton, J. F. (2011). Autonomic-immune-vascular interaction: an emerging concept for neurogenic hypertension. Hypertension, 57, 1026–1033.CrossRefPubMedPubMedCentral

10.

Muller, D. N., Kvakan, H., & Luft, F. C. (2011). Immune-related effects in hypertension and target-organ damage. Current Opinion in Nephrology and Hypertension, 20, 113–117.CrossRefPubMed

11.

Touyz, R. M. (2005). Molecular and cellular mechanisms in vascular injury in hypertension: Role of angiotensin II. Current Opinion in Nephrology and Hypertension, 14, 125–131.CrossRefPubMed

12.

Baylis, C. (2012). Nitric oxide synthase derangements and hypertension in kidney disease. Current Opinion in Nephrology and Hypertension, 21, 1–6.CrossRefPubMedPubMedCentral

13.

Rodrigo, R., Gonzalez, J., & Paoletto, F. (2011). The role of oxidative stress in the pathophysiology of hypertension. Hypertension Research: Official Journal of the Japanese Society of Hypertension, 34, 431–440.CrossRef

14.

Wilcox, C. S. (2005). Oxidative stress and nitric oxide deficiency in the kidney: A critical link to hypertension? American Journal of Physiology. Regulatory, Integrative and Comparative Physiology, 289, R913–R935.CrossRefPubMed

15.

Vaziri, N. D. (2004). Roles of oxidative stress and antioxidant therapy in chronic kidney disease and hypertension. Current Opinion in Nephrology and Hypertension, 13, 93–99.CrossRefPubMed

16.

Touyz, R. M. (2004). Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: What is the clinical significance? Hypertension, 44, 248–252.CrossRefPubMed

17.

Droge, W. (2002). Free radicals in the physiological control of cell function. Physiological Reviews, 82, 47–95.CrossRefPubMed

18.

Kakihana, T., Nagata, K., & Sitia, R. (2012). Peroxides and peroxidases in the endoplasmic reticulum: Integrating redox homeostasis and oxidative folding. Antioxidants and Redox Signaling, 16, 763–771.CrossRefPubMed

19.

Laurindo, F. R., Pescatore, L. A., & Fernandes Dde, C. (2012). Protein disulfide isomerase in redox cell signaling and homeostasis. Free Radical Biology and Medicine, 52, 1954–1969.CrossRefPubMed

20.

Lee, J., Giordano, S., & Zhang, J. (2012). Autophagy, mitochondria and oxidative stress: Cross-talk and redox signalling. The Biochemical Journal, 441, 523–540.CrossRefPubMed

21.

Touyz, R. M., Briones, A. M., Sedeek, M., Burger, D., & Montezano, A. C. (2011). NOX isoforms and reactive oxygen species in vascular health. Molecular Interventions, 11, 27–35.CrossRefPubMed

22.

Vaziri, N. D., & Rodriguez-Iturbe, B. (2006). Mechanisms of disease: Oxidative stress and inflammation in the pathogenesis of hypertension. Nature Clinical Practice Nephrology, 2, 582–593.CrossRefPubMed

23.

Touyz, R. M., & Schiffrin, E. L. (2004). Reactive oxygen species in vascular biology: Implications in hypertension. Histochemistry and Cell Biology, 122, 339–352.CrossRefPubMed

24.

Touyz, R. M., & Briones, A. M. (2011). Reactive oxygen species and vascular biology: Implications in human hypertension. Hypertension Research: Official Journal of the Japanese Society of Hypertension, 34, 5–14.CrossRef

25.

Chen, D. D., Dong, Y. G., Yuan, H., & Chen, A. F. (2012). Endothelin 1 activation of endothelin A receptor/NADPH oxidase pathway and diminished antioxidants critically contribute to endothelial progenitor cell reduction and dysfunction in salt-sensitive hypertension. Hypertension, 59, 1037–1043.CrossRefPubMed

26.

Huang, B. S., Zheng, H., Tan, J., Patel, K. P., & Leenen, F. H. (2011). Regulation of hypothalamic renin–angiotensin system and oxidative stress by aldosterone. Experimental Physiology, 96, 1028–1038.CrossRefPubMedPubMedCentral

27.

Schupp, N., Kolkhof, P., Queisser, N., Gartner, S., Schmid, U., Kretschmer, A., et al. (2011). Mineralocorticoid receptor-mediated DNA damage in kidneys of DOCA-salt hypertensive rats. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology, 25, 968–978.CrossRef

28.

Kimura, M., Umegaki, K., Kasuya, Y., Sugisawa, A., & Higuchi, M. (2002). The relation between single/double or repeated tea catechin ingestions and plasma antioxidant activity in humans. European Journal of Clinical Nutrition, 56, 1186–1193.CrossRefPubMed

29.

Frei, B., & Higdon, J. V. (2003). Antioxidant activity of tea polyphenols in vivo: Evidence from animal studies. The Journal of Nutrition, 133, 3275S–3284S.PubMed

30.

Higdon, J. V., & Frei, B. (2003). Tea catechins and polyphenols: Health effects, metabolism, and antioxidant functions. Critical Reviews in Food Science and Nutrition, 43, 89–143.CrossRefPubMed

31.

Thomas, R., & Kim, M. H. (2005). Epigallocatechin gallate inhibits HIF-1α degradation in prostate cancer cells. Biochemical and Biophysical Research Communications, 334, 543–548.CrossRefPubMed

32.

Zaveri, N. T. (2006). Green tea and its polyphenolic catechins: Medicinal uses in cancer and noncancer applications. Life Sciences, 78, 2073–2080.CrossRefPubMed

33.

Nakachi, K., Matsuyama, S., Miyake, S., Suganuma, M., & Imai, K. (2000). Preventive effects of drinking green tea on cancer and cardiovascular disease: Epidemiological evidence for multiple targeting prevention. BioFactors, 13, 49–54.CrossRefPubMed

34.

Kang, W. S., Lim, I. H., Yuk, D. Y., Chung, K. H., Park, J. B., Yoo, H. S., et al. (1999). Antithrombotic activities of green tea catechins and (–)-epigallocatechin gallate. Thrombosis Research, 96, 229–237.CrossRefPubMed

35.

Townsend, P. A., Scarabelli, T. M., Pasini, E., Gitti, G., Menegazzi, M., Suzuki, H., et al. (2004). Epigallocatechin-3-gallate inhibits STAT-1 activation and protects cardiac myocytes from ischemia/reperfusion-induced apoptosis. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology, 18, 1621–1623.

36.

Lorenz, M., Wessler, S., Follmann, E., Michaelis, W., Dusterhoft, T., Baumann, G., et al. (2004). A constituent of green tea, epigallocatechin-3-gallate, activates endothelial nitric oxide synthase by a phosphatidylinositol-3-OH-kinase-, cAMP-dependent protein kinase-, and Akt-dependent pathway and leads to endothelial-dependent vasorelaxation. The Journal of Biological Chemistry, 279, 6190–6195.CrossRefPubMed

37.

Baluchnejadmojarad, T., & Roghani, M. (2011). Chronic epigallocatechin-3-gallate ameliorates learning and memory deficits in diabetic rats via modulation of nitric oxide and oxidative stress. Behavioural Brain Research, 224, 305–310.CrossRefPubMed

38.

Baba, Y., Sonoda, J. I., Hayashi, S., Tosuji, N., Sonoda, S., Makisumi, K., et al. (2012). Reduction of oxidative stress in liver cancer patients by oral green tea polyphenol tablets during hepatic arterial infusion chemotherapy. Experimental and Therapeutic Medicine, 4, 452–458.PubMedPubMedCentral

39.

Kochi, T., Shimizu, M., Terakura, D., Baba, A., Ohno, T., Kubota, M., et al. (2014). Non-alcoholic steatohepatitis and preneoplastic lesions develop in the liver of obese and hypertensive rats: Suppressing effects of EGCG on the development of liver lesions. Cancer Letters, 342, 60–69.CrossRefPubMed

40.

Wang, M. H., Chang, W. J., Soung, H. S., & Chang, K. C. (2012). (–)-Epigallocatechin-3-gallate decreases the impairment in learning and memory in spontaneous hypertension rats. Behavioural Pharmacology, 23, 771–780.CrossRefPubMed

41.

Hodgson, J. M., & Croft, K. D. (2010). Tea flavonoids and cardiovascular health. Molecular Aspects of Medicine, 31, 495–502.CrossRefPubMed

42.

Babu, P. V., & Liu, D. (2008). Green tea catechins and cardiovascular health: An update. Current Medicinal Chemistry, 15, 1840–1850.CrossRefPubMedPubMedCentral

43.

Potenza, M. A., Marasciulo, F. L., Tarquinio, M., Tiravanti, E., Colantuono, G., Federici, A., et al. (2007). EGCG, a green tea polyphenol, improves endothelial function and insulin sensitivity, reduces blood pressure, and protects against myocardial I/R injury in SHR. American Journal of Physiology. Endocrinology and metabolism, 292, E1378–E1387.CrossRefPubMed

44.

Su, Q., Qin, D. N., Wang, F. X., Ren, J., Li, H. B., Zhang, M., et al. (2014). Inhibition of reactive oxygen species in hypothalamic paraventricular nucleus attenuates the renin-angiotensin system and proinflammatory cytokines in hypertension. Toxicology and Applied Pharmacology, 276, 115–120.CrossRefPubMed

45.

Kang, Y. M., Ma, Y., Zheng, J. P., Elks, C., Sriramula, S., Yang, Z. M., et al. (2009). Brain nuclear factor-kappa B activation contributes to neurohumoral excitation in angiotensin II-induced hypertension. Cardiovascular Research, 82, 503–512.CrossRefPubMedPubMedCentral

46.

Cardinale, J. P., Sriramula, S., Mariappan, N., Agarwal, D., & Francis, J. (2012). Angiotensin II-induced hypertension is modulated by nuclear factor-kappa B in the paraventricular nucleus. Hypertension, 59, 113–121.CrossRefPubMed

47.

Zimmerman, M. C., Lazartigues, E., Sharma, R. V., & Davisson, R. L. (2004). Hypertension caused by angiotensin II infusion involves increased superoxide production in the central nervous system. Circulation Research, 95, 210–216.CrossRefPubMed

48.

Kang, Y. M., Chen, J. Y., Ouyang, W., Qiao, J. T., Reyes-Vazquez, C., & Dafny, N. (2004). Serotonin modulates hypothalamic neuronal activity. The International Journal of Neuroscience, 114, 299–319.CrossRefPubMed

49.

Han, Y., Fan, Z. D., Yuan, N., Xie, G. Q., Gao, J., De, W., et al. (2011). Superoxide anions in the paraventricular nucleus mediate the enhanced cardiac sympathetic afferent reflex and sympathetic activity in renovascular hypertensive rats. Journal of Applied Physiology, 110, 646–652.CrossRefPubMed

50.

Zhu, G. Q., Xu, Y., Zhou, L. M., Li, Y. H., Fan, L. M., Wang, W., et al. (2009). Enhanced cardiac sympathetic afferent reflex involved in sympathetic overactivity in renovascular hypertensive rats. Experimental Physiology, 94, 785–794.CrossRefPubMed

51.

Kang, Y. M., He, R. L., Yang, L. M., Qin, D. N., Guggilam, A., Elks, C., et al. (2009). Brain tumour necrosis factor-alpha modulates neurotransmitters in hypothalamic paraventricular nucleus in heart failure. Cardiovascular Research, 83, 737–746.CrossRefPubMedPubMedCentral

52.

Qi, J., Zhang, D. M., Suo, Y. P., Song, X. A., Yu, X. J., Elks, C., et al. (2013). Renin–angiotensin system modulates neurotransmitters in the paraventricular nucleus and contributes to angiotensin II-induced hypertensive response. Cardiovascular Toxicology, 13, 48–54.CrossRefPubMed

53.

Li, H. B., Qin, D. N., Ma, L., Miao, Y. W., Zhang, D. M., Lu, Y., et al. (2014). Chronic infusion of lisinopril into hypothalamic paraventricular nucleus modulates cytokines and attenuates oxidative stress in rostral ventrolateral medulla in hypertension. Toxicology and Applied Pharmacology, 279, 141–149.CrossRefPubMed

54.

Gao, L., Wang, W., Li, Y. L., Schultz, H. D., Liu, D., Cornish, K. G., et al. (2005). Sympathoexcitation by central ANG II: Roles for AT1 receptor upregulation and NAD(P)H oxidase in RVLM. American Journal of Physiology. Heart and circulatory Physiology, 288, H2271–H2279.CrossRefPubMed

55.

Kang, Y. M., Zhang, Z. H., Johnson, R. F., Yu, Y., Beltz, T., Johnson, A. K., et al. (2006). Novel effect of mineralocorticoid receptor antagonism to reduce proinflammatory cytokines and hypothalamic activation in rats with ischemia-induced heart failure. Circulation Research, 99, 758–766.CrossRefPubMed

56.

Agarwal, D., Welsch, M. A., Keller, J. N., & Francis, J. (2011). Chronic exercise modulates RAS components and improves balance between pro- and anti-inflammatory cytokines in the brain of SHR. Basic Research in Cardiology, 106, 1069–1085.CrossRefPubMedPubMedCentral

57.

Coote, J. H. (2007). Landmarks in understanding the central nervous control of the cardiovascular system. Experimental Physiology, 92, 3–18.CrossRefPubMed

58.

Joyner, M. J., Charkoudian, N., & Wallin, B. G. (2008). A sympathetic view of the sympathetic nervous system and human blood pressure regulation. Experimental Physiology, 93, 715–724.CrossRefPubMedPubMedCentral

59.

Martinez-Maldonado, M. (1991). Pathophysiology of renovascular hypertension. Hypertension, 17, 707–719.CrossRefPubMed

60.

Katholi, R. E., Whitlow, P. L., Winternitz, S. R., & Oparil, S. (1982). Importance of the renal nerves in established two-kidney, one clip Goldblatt hypertension. Hypertension, 4, 166–174.PubMed

61.

Cohn, H. I., Harris, D. M., Pesant, S., Pfeiffer, M., Zhou, R. H., Koch, W. J., et al. (2008). Inhibition of vascular smooth muscle G protein-coupled receptor kinase 2 enhances α1D-adrenergic receptor constriction. American Journal of Physiology. Heart and circulatory physiology, 295, H1695–H1704.CrossRefPubMedPubMedCentral

62.

Campos, R. R., Oliveira-Sales, E. B., Nishi, E. E., Boim, M. A., Dolnikoff, M. S., & Bergamaschi, C. T. (2011). The role of oxidative stress in renovascular hypertension. Clinical and Experimental Pharmacology and Physiology, 38, 144–152.CrossRefPubMed

63.

Chen, A. D., Zhang, S. J., Yuan, N., Xu, Y., De, W., Gao, X. Y., et al. (2011). Angiotensin AT1 receptors in paraventricular nucleus contribute to sympathetic activation and enhanced cardiac sympathetic afferent reflex in renovascular hypertensive rats. Experimental Physiology, 96, 94–103.CrossRefPubMed

64.

Maliszewska-Scislo, M., Chen, H., Augustyniak, R. A., Seth, D., & Rossi, N. F. (2008). Subfornical organ differentially modulates baroreflex function in normotensive and two-kidney, one-clip hypertensive rats. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology, 295, R741–R750.CrossRefPubMedPubMedCentral

65.

Kishi, T., & Hirooka, Y. (2012). Oxidative stress in the brain causes hypertension via sympathoexcitation. Frontiers in Physiology, 3, 335.CrossRefPubMedPubMedCentral

66.

Wu, K. L., Chan, S. H., & Chan, J. Y. (2012). Neuroinflammation and oxidative stress in rostral ventrolateral medulla contribute to neurogenic hypertension induced by systemic inflammation. Journal of Neuroinflammation, 9, 212.CrossRefPubMedPubMedCentral

67.

Zimmerman, M. C., Sharma, R. V., & Davisson, R. L. (2005). Superoxide mediates angiotensin II-induced influx of extracellular calcium in neural cells. Hypertension, 45, 717–723.CrossRefPubMed

68.

Shi, Z., Gan, X. B., Fan, Z. D., Zhang, F., Zhou, Y. B., Gao, X. Y., et al. (2011). Inflammatory cytokines in paraventricular nucleus modulate sympathetic activity and cardiac sympathetic afferent reflex in rats. Acta Physiologica (Oxf), 203, 289–297.CrossRef

69.

Taubert, D., Roesen, R., & Schomig, E. (2007). Effect of cocoa and tea intake on blood pressure: A meta-analysis. Archives of Internal Medicine, 167, 626–634.CrossRefPubMed

70.

Liu, P. L., Liu, J. T., Kuo, H. F., Chong, I. W., & Hsieh, C. C. (2014). Epigallocatechin gallate attenuates proliferation and oxidative stress in human vascular smooth muscle cells induced by interleukin-1beta via heme oxygenase-1. Mediators of Inflammation, 2014, 523684.PubMedPubMedCentral

71.

Steffen, Y., Gruber, C., Schewe, T., & Sies, H. (2008). Mono-O-methylated flavanols and other flavonoids as inhibitors of endothelial NADPH oxidase. Archives of Biochemistry and Biophysics, 469, 209–219.CrossRefPubMed

72.

Rodrigo, R. (2012). Prevention of postoperative atrial fibrillation: Novel and safe strategy based on the modulation of the antioxidant system. Frontiers in Physiology, 3, 93.CrossRefPubMedPubMedCentral

73.

Simic, D. V., Mimic-Oka, J., Pljesa-Ercegovac, M., Savic-Radojevic, A., Opacic, M., Matic, D., et al. (2006). Byproducts of oxidative protein damage and antioxidant enzyme activities in plasma of patients with different degrees of essential hypertension. Journal of Human Hypertension, 20, 149–155.CrossRefPubMed

74.

Roghani, M., & Baluchnejadmojarad, T. (2009). Chronic epigallocatechin-gallate improves aortic reactivity of diabetic rats: underlying mechanisms. Vascular Pharmacology, 51, 84–89.CrossRefPubMed

75.

Antonello, M., Montemurro, D., Bolognesi, M., Di Pascoli, M., Piva, A., Grego, F., et al. (2007). Prevention of hypertension, cardiovascular damage and endothelial dysfunction with green tea extracts. American Journal of Hypertension, 20, 1321–1328.CrossRefPubMed

76.

Khalaf, A. A., Moselhy, W. A., & Abdel-Hamed, M. I. (2012). The protective effect of green tea extract on lead induced oxidative and DNA damage on rat brain. Neurotoxicology, 33, 280–289.CrossRefPubMed

Titel: Paraventricular Nucleus Infusion of Epigallocatechin-3-O-Gallate Improves Renovascular Hypertension
verfasst von: Qiu-Yue Yi
Jie Qi
Xiao-Jing Yu
Hong-Bao Li
Yan Zhang
Qing Su
Tao Shi
Dong-Mei Zhang
Jing Guo
Zhi-Peng Feng
Mo-Lin Wang
Guo-Qing Zhu
Jin-Jun Liu
Xiao-Lian Shi
Yu-Ming Kang
Publikationsdatum: 11.07.2015
Verlag: Springer US
Erschienen in: Cardiovascular Toxicology / Ausgabe 3/2016
Print ISSN: 1530-7905
Elektronische ISSN: 1559-0259
DOI: https://doi.org/10.1007/s12012-015-9335-x

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2016

Apigenin Attenuates β-Receptor-Stimulated Myocardial Injury Via Safeguarding Cardiac Functions and Escalation of Antioxidant Defence System

Salusin β Within the Nucleus Tractus Solitarii Suppresses Blood Pressure Via Inhibiting the Activities of Presympathetic Neurons in the Rostral Ventrolateral Medulla in Spontaneously Hypertensive Rats

Biomarkers Associated with Ischemic Stroke in Diabetes Mellitus Patients

Peroxisome Proliferator-Activated Receptor-α Inhibition Protects Against Doxorubicin-Induced Cardiotoxicity in Mice

Air Pollution-Induced Vascular Dysfunction: Potential Role of Endothelin-1 (ET-1) System

Cyanidin-3-O-glucoside Induces Apoptosis and Inhibits Migration of Tumor Necrosis Factor-α-Treated Rat Aortic Smooth Muscle Cells